Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Account Payables (2016 - 2025)

China Pharma Holdings' Change in Account Payables history spans 16 years, with the latest figure at $292259.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 287.64% year-over-year to $292259.0; the TTM value through Dec 2025 reached $650309.0, up 188.61%, while the annual FY2025 figure was $650309.0, 188.61% up from the prior year.
  • Change in Account Payables reached $292259.0 in Q4 2025 per CPHI's latest filing, up from $54437.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $442807.0 in Q3 2023 to a low of -$505339.0 in Q2 2024.
  • Average Change in Account Payables over 5 years is -$14603.8, with a median of $25512.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: soared 3045.77% in 2023, then plummeted 414.87% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $311018.0 in 2021, then dropped by 23.32% to $238485.0 in 2022, then crashed by 54.75% to $107922.0 in 2023, then plummeted by 244.32% to -$155753.0 in 2024, then soared by 287.64% to $292259.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Change in Account Payables are $292259.0 (Q4 2025), $54437.0 (Q3 2025), and -$19322.0 (Q2 2025).